NanoViricides, Inc. (NASDAQ:NNVC)

PRESS RELEASE

published on 10/15/2024 at 12:30, 1 year 11 months ago

NanoViricides President Dr. Diwan Interviwed in PODD Podcast; He Explains the Revolutionary Clinical Stage Broad-Spectrum Antiviral NV-387, and the Potential of the Platform to Revolutionize Fields Beyond Virology
NanoViricides, Inc. announces interview with Dr. Diwan discussing revolutionary broad-spectrum antiviral clinical drug candidate NV-387 and innovative nanoviricide technology platform

NV-387 Clinical Trials NanoViricides Inc. Antiviral NanoViricides Technology
BRIEF

published on 10/08/2024 at 12:35, 1 year 11 months ago

NanoViricides to Address AMR Summit 2024 on Innovative Drug Technologies

Antimicrobial Resistance Clinical Trials AMR Summit 2024 NanoViricides Technology NV-387 Drug
BRIEF

published on 10/08/2024 at 12:35, 1 year 11 months ago

NanoViricides participera au Sommet AMR 2024 sur les technologies pharmaceutiques innovantes

Essais Cliniques Résistance Aux Antimicrobiens Sommet AMR 2024 Technologie Des Nanoviricides Médicament NV-387
PRESS RELEASE

published on 10/08/2024 at 12:30, 1 year 11 months ago

NanoViricides to Present at the Global AMR Summit 2024 Tomorrow
Dr. Diwan to discuss NanoViricides' pathogen-directed attack technology combating AMR at the Global AMR Summit, highlighting the 'shape-shifting' nanoviricide platform

NanoViricides Antiviral AMR Nanomedicines Pathogen-directed Therapy
BRIEF

published on 09/30/2024 at 12:35, 1 year 11 months ago

NanoViricides Reports Annual Financials and Advances NV-387 to Phase II Trials

NanoViricides NV-387 Financial Report Antiviral Drug Phase II Trials
BRIEF

published on 09/30/2024 at 12:35, 1 year 11 months ago

NanoViricides publie ses résultats financiers annuels et fait progresser le NV-387 vers les essais de phase II

NanoViricides NV-387 Rapport Financier Médicament Antiviral Essais De Phase II
PRESS RELEASE

published on 09/30/2024 at 12:30, 1 year 11 months ago

NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include RSV, Influenza, MPOX/Smallpox, COVID
NanoViricides, Inc. reports filing of Annual Report on Form 10-K for fiscal year 2024, financial updates, and plans for Phase II clinical trials of antiviral drug NV-387

NanoViricides NV-387 Financial Updates Form 10-K Phase II Clinical Trials
BRIEF

published on 09/26/2024 at 12:35, 2 years ago

NanoViricides Signs Comprehensive Antiviral Drug Agreement With TheraCour Pharma

NanoViricides NV-387 Antiviral Drugs TheraCour Pharma Trojan Horse Drugs
BRIEF

published on 09/26/2024 at 12:35, 2 years ago

NanoViricides signe un accord global sur les médicaments antiviraux avec TheraCour Pharma

NanoViricides NV-387 Médicaments Antiviraux TheraCour Pharma Drogues Du Type Cheval De Troie
PRESS RELEASE

published on 09/26/2024 at 12:30, 2 years ago

NanoViricides Executes an Agreement Encompassing All Antiviral Drug Treatments With Theracour, Including “Trojan Horse” Drugs
NanoViricides, Inc. obtains right of first refusal for antiviral drug developments from TheraCour Pharma, expands drug portfolio with new MOU and revolutionary nanoviricide technology, including NV-387 for multiple viral infections

NV-387 Antiviral Drugs NanoViricides Inc. TheraCour Pharma Nanoviricide Technology

Published on 09/29/2026 at 13:00, 20 minutes ago

Formation Metals Appoints Mining Finance Icon Terry Salman, C.M. as Senior Strategic Advisor Ahead of Maiden Resource at the N2 Property
Published on 09/29/2026 at 13:00, 20 minutes ago

Eagle Plains Partner Sun Summit Completes 2026 Program at the Theory Project, Toodoggone District, BC
Published on 09/29/2026 at 13:00, 20 minutes ago

Kalo Gold Confirm Gold-Silver Electrum at Wainikoro, Sharpening Drill Targeting at Vatu Aurum Project, Fiji
Published on 09/29/2026 at 13:00, 20 minutes ago

INEO to Present at OTC Markets AI & Technology Virtual Investor Conference on October 1, 2026
Published on 09/29/2026 at 13:00, 20 minutes ago

Temas and SAGA Advance RCL to Stage 2 Targeting Titanium, Vanadium and Iron Products in Preparation for Pilot Studies

View all ACCESSWIRE

Published on 09/29/2026 at 12:24, 55 minutes ago

Amundi Physical Metals plc: UK Final Terms
Published on 09/29/2026 at 12:20, 1 hour ago

Amundi Physical Metals plc: Final Terms
Published on 09/29/2026 at 12:07, 1 hour 13 minutes ago

JDC Group Launches First AI-Agent for the German Insurance Market
Published on 09/29/2026 at 12:05, 1 hour 15 minutes ago

H.I.G. Capital Completes Acquisition of Torque
Published on 09/29/2026 at 12:04, 1 hour 16 minutes ago

LAIQON - EU AI ETF reaches EUR 60 million mark

View all EQS

Published on 09/29/2026 at 12:15, 1 hour 5 minutes ago

NRJ GROUP - Affaire Fun Radio - Report du délibéré de la Cour d'appel
Published on 09/29/2026 at 08:45, 4 hours 35 minutes ago

Cegedim Santé réinvente l’accès à l’information médicale en déployant l’Assistant by Claude Bernard IA sur toutes ses solutions de médecine de ville
Published on 09/28/2026 at 17:54, 19 hours 25 minutes ago

Reporting on share buyback transactions carried out between September 21 and September 25, 2026
Published on 09/28/2026 at 17:54, 19 hours 25 minutes ago

Déclaration de rachats d'actions effectués par la Compagnie de Saint-Gobain entre le 21 et le 25 septembre 2026
Published on 09/28/2026 at 17:45, 19 hours 35 minutes ago

Weekly share buyback

View all LES ECHOS COMFI WIRE

News